Category: Biolase Technology Inc.
Hedge fund giant BlackRock boosted its stake in a number of medical device companies last year, but cut its holdings in others, regulatory filings show.
Wright Medical Group Inc.
, Align Technology Inc.
, ArthroCare Corp.
, AtriCure Inc.
, Biolase Technology Inc.
, BlackRock Inc.
, Cutera Inc.
, Cynosure Inc.
, Dentsply International Inc.
, HeartWare International Inc.
, ICU Medical Inc.
, Medical Action Industries Inc.
, Merit Medical Systems Inc.
, NxStage Medical Inc.
, Thoratec Corp.
Medical lasers maker Biolase is still examining "strategic alternatives" for the company as its slashes about $1.3 million from its payroll and posts continued quarterly losses.
California medtech company Biolase (NSDQ:BIOL) is looking to slim down ahead of a potential acquisition as the company examines its "strategic alternatives."
Biolase ties the bow on a $5 million private placement with Oracle Investment Management it plans to use to pay down debt.
Biolase (NSDQ:BIOL) said it closed a $5 million private placement with Oracle Investment Management.
The surgical laser maker sold off a little more than 1.9 million shares for $2.57 each, with the deal closing on Feb. 10. The money is expected to go toward paying down its $4.6 million credit facility with Comerica Bank, according to chairman & CEO Federico Pignatelli .
Medical lasers maker Biolase adds 2 new directors to its board and engages Piper Jaffray & Co. as its exclusive financial advisor as it continues to evaluate a potential sale.
Biolase shares tank after the medical device company reports gaping 3rd-quarter losses and sacks its sales vice presidents, saying it will court a potential acquirer.
Biolase and Auris Surgical Robotics ink a deal to co-develop a cataract-removal ophthalmological robot.
Biolase (NSDQ:BIOL) and Auris Surgical Robotics said they've inked a deal to collaborate on developing a cataract-removal ophthalmologic robot.
A group of Biolase shareholders are suing in a class action lawsuit accusing company directors of lying about its financial struggles.
Biolase (NSDQ:BLTI) is facing a lawsuit brought by shareholders accusing the company of hiding problems by lying on quarterly earnings reports. The lawsuit claims Biolase and its directors concealed liquidity and solvency issues as well as under-performing sales.